Alaunos Therapeutics, Inc.
TCRT
$1.55
-$0.02-1.27%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -50.00% | -70.00% | -44.44% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -50.00% | -70.00% | -44.44% | 0.00% | 0.00% |
| Cost of Revenue | 179.29% | 146.92% | 275.21% | -33.79% | -87.97% |
| Gross Profit | -181.65% | -150.70% | -283.33% | 33.94% | 88.08% |
| SG&A Expenses | -30.03% | -24.60% | -35.68% | -47.63% | -59.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.47% | -0.60% | -12.28% | -45.06% | -70.08% |
| Operating Income | -0.55% | 0.43% | 12.22% | 45.09% | 70.11% |
| Income Before Tax | -0.43% | -0.93% | 10.77% | 65.83% | 79.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.43% | -0.93% | 10.77% | 65.83% | 79.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.43% | -0.93% | 10.77% | 65.83% | 79.13% |
| EBIT | -0.55% | 0.43% | 12.22% | 45.09% | 70.11% |
| EBITDA | -0.11% | 0.64% | 12.22% | 43.25% | 67.93% |
| EPS Basic | 24.19% | 17.27% | 22.77% | 68.86% | 79.38% |
| Normalized Basic EPS | 26.03% | 19.06% | 24.33% | 48.99% | 69.92% |
| EPS Diluted | 24.19% | 17.27% | 22.77% | 68.86% | 79.38% |
| Normalized Diluted EPS | 26.03% | 19.06% | 24.33% | 48.99% | 69.92% |
| Average Basic Shares Outstanding | 37.17% | 27.00% | 21.58% | 10.27% | 1.20% |
| Average Diluted Shares Outstanding | 37.17% | 27.00% | 21.58% | 10.27% | 1.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |